AdAlta Investor Briefing 2021

This video series covers AdAlta’s 2021 Investor Briefing. At the briefing, CEO Tim Oldham, VP Clinical Product Development Claudia Gregorio-King and Prof Glen Westall, a leading respiratory and lung fibrosis specialist, discussed the Company’s strategic progress and top-line results from Part A of the Phase I clinical trial of AD-214. Highlight Tim Oldham, CEO and Managing Director AdAlta Investor Briefing March 10, 2021 Adalta (ASX:1AD) Chief Executive Officer & Managing Director, Dr Tim Oldham, talked about the positive progress from AdAlta’s AD-214 Part A of the Phase I trial and how the results. Investor Update: Tim Oldham, CEO and Managing Director. Investor Briefing March 10, 2021 Adalta (ASX:1AD) Chief Executive Officer & Managing Director, Dr Tim Oldham, talked about the positive progress from AdAlta’s AD-214 Part A of the Phase I trial and how the results have led to expanded opportunities for the company, the initial clinical validation i-body platform and how it has now also strengthened AdAlta’s asset creation options. Dr Oldham also discussed the significant milestones achieved since March 2020. AD-214 Phase I HV SAD top-line results Claudia Gregorio-King, Vice President, Clinical Product Development AdAlta Investor Briefing March 10, 2021 AdAlta (ASX:1AD) Vice President, Clinical Product Development Claudia Gregorio-King, gave a detailed explanation of the preliminary healthy volunteer single dose results. In the discussion, Claudia explained AD-214’s excellent safety profile, how AD-214 engages the CXCR4 receptor, and how the results showed that receptor occupancy was sustained at high levels for an extended period of time. Context: importance for IPF Professor Glen Westall, Leading respiratory and lung fibrosis specialist AdAlta Investor Briefing March 10, 2021 Leading respiratory and lung fibrosis specialist, Professor Glen Westall, spoke about the global environment for lung fibrosis, the limitations of available treatments and the significance of AdAlta’s recent initial clinical results and AD-214 development approach. Looking ahead Tim Oldham, CEO and Managing Director AdAlta Investor Briefing March 10, 2021 AdAlta’s (ASX:1AD) CEO and Managing Director Tom Oldham discussed AdAlta’s long- and short-term strategic goals, reaffirming benefits of the redesigned Phase I program for AD-214. Dr Oldham also explained how clinical and commercial validation of i-body platform is unlocking new possibilities for pipeline expansion, allowing AdAlta to become a multi-asset company. Full presentation pack

The release as fetched from its publisher. adalta.com.au ↗